Tag Archives: january

Vistin Pharma ASA: Dividend of NOK 0.75 per share

Posted: January 14, 2024 at 2:35 am

Oslo, Norway, 11 January 2024

Originally posted here:
Vistin Pharma ASA: Dividend of NOK 0.75 per share

Posted in Global News Feed | Comments Off on Vistin Pharma ASA: Dividend of NOK 0.75 per share

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Posted: January 14, 2024 at 2:35 am

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —

Read more from the original source:
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Posted in Global News Feed | Comments Off on HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Posted: January 14, 2024 at 2:35 am

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, January 16, 2024, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on January 8, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

View post:
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Posted in Global News Feed | Comments Off on TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted: January 14, 2024 at 2:35 am

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.

Go here to read the rest:
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted in Global News Feed | Comments Off on Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

Posted: January 14, 2024 at 2:35 am

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST.

Read this article:
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

Posted in Global News Feed | Comments Off on Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…

Posted: January 6, 2024 at 2:37 am

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.

Originally posted here:
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,...

Posted in Global News Feed | Comments Off on SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Posted: January 6, 2024 at 2:37 am

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.

Read more:
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Posted in Global News Feed | Comments Off on OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Posted: January 6, 2024 at 2:37 am

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT.

Read the original:
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Posted in Global News Feed | Comments Off on ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)